Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
暂无分享,去创建一个
M. Shimada | M. Nishi | H. Kashihara | Toshiaki Yoshimoto | C. Takasu | K. Yoshikawa | Jun Higashijima | T. Tokunaga | T. Miyatani | Yukako Takehara | T. Yoshimoto
[1] B. Godman,et al. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis , 2018, BioDrugs.
[2] Y. Tajima,et al. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature , 2018, Journal of Medical Case Reports.
[3] K. Muro,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] L. Rosen,et al. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars , 2017, Targeted Oncology.
[5] T. Iida,et al. A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab , 2016, Internal medicine.
[6] T. Tsuzuki,et al. The effects of bevacizumab on intestinal anastomotic healing in rabbits , 2016, Surgery Today.
[7] S. Barni,et al. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies , 2016, Annals of surgery.
[8] J. Lefèvre,et al. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer. , 2015, Annals of surgery.
[9] M. Yano,et al. Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report , 2015, International journal of surgery case reports.
[10] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[11] C. Morosi,et al. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. , 2015, Critical reviews in oncology/hematology.
[12] R. Steele,et al. Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks , 2015, The British journal of surgery.
[13] H. Shinozaki,et al. Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. , 2015, Japanese journal of clinical oncology.
[14] Yang Yao,et al. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups , 2014, European Journal of Clinical Pharmacology.
[15] E. Pavlidis,et al. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. , 2013, World journal of gastroenterology.
[16] D. Tyler,et al. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. , 2012, Journal of the American College of Surgeons.
[17] Masahiro Yoshida,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.
[18] M. Pocard,et al. Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy. , 2011, Clinics and research in hepatology and gastroenterology.
[19] K. Topouridou,et al. The effect of bevacizumab on colon anastomotic healing in rats , 2010, International Journal of Colorectal Disease.
[20] R. Barakat,et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. , 2010, Gynecologic oncology.
[21] X Allen Li,et al. Radiation dose-volume effects in the stomach and small bowel. , 2010, International journal of radiation oncology, biology, physics.
[22] Shenhong Wu,et al. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. , 2009, The Lancet. Oncology.
[23] F. Viret,et al. Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients , 2009, Annals of Surgical Oncology.
[24] L. Sidéris,et al. Complications after colorectal anastomosis in a patient with metastatic rectal cancer treated with systemic chemotherapy and bevacizumab. , 2008, Canadian journal of surgery. Journal canadien de chirurgie.
[25] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[26] S. Huerta,et al. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. , 2006, Current surgery.
[27] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[28] Y. Terashima,et al. Two Cases of Emergency Operations in Patients Undergoing Bevacizumab Treatment , 2010 .
[29] L. Ellis,et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.